Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| Address 2: | Axis Business Park |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | NSD |
| CEO: | Filippo Petti |
| Employees: | 107 |
Every public company routinely posts a webcast or slides on its website after it presents. We encourage you to review the ones that interest you and get a glimpse at what institutions have been seeing this week.
Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant
Celyad Oncology is a biopharmaceutical company, specialized in cell therapy. It develops technologies and treatments to treat severe diseases with poor prognosis. The company focuses on Immuno oncology, Cardiology, and Medical devices. Its main product candidates include CAR-T and C-Cure. The firm has CYAD-01 and CYAD-02 programs in pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CATH and C-CATHez and CARDIO 3 BIOSCIENCES. The firm has Cardiology and Immuno-oncology operating segments.
| Website: | www.celyad.com |
| Email: | investors@celyad.com |
| Main Phone: | +32 10394100 |
| Address: | Rue Edouard Belin 2 |
| Address 2: | Axis Business Park |
| City / Town: | Mont-Saint-Guibert |
| Country: | BEL |
| Postal Code: | 1435 |
| Exchange: | NSD |
| CEO: | Filippo Petti |
| Employees: | 107 |
Every public company routinely posts a webcast or slides on its website after it presents. We encourage you to review the ones that interest you and get a glimpse at what institutions have been seeing this week.
Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant
| Last Price 10.27 | Change $ 0.15 | Change % 1.48 | Tick N/A |
| Bid N/A | Bid Size 0.00 | Ask 11.00 | Ask Size 600.00 |
| Open 10.32 | High 10.32 | Low 10.25 | Prev Close 10.12 |
| Last Trade | Volume 3,739 | 52 Wk Hi 14.98 | 52 Wk Low 4.10 |
| Market Cap 143.2 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 13,942,344.00 | EPS (TTM) -3.86 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 74 | 74 | 74 | 74 |
| Low Target Price Estimate | 49 | 74 | 74 | 49 |
| Mean Target Price Estimate | 61.5 | 74 | 74 | 61.5 |
| Standard Deviation | 17.68 | 0 | 0 | 17.68 |
| Date of Most Recent Estimate | 05/31/18 | 03/23/18 | 03/23/18 | 05/31/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 7 | 2018-05-23 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 58 | 2018-05-18 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-18 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 8 | 2018-05-16 |
| 424B5 | Prospectus filed under Rule 424(b)(5) | 109 | 2018-05-16 |
| FWP | Free Writing Prospectus | 4 | 2018-05-16 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 37 | 2018-05-11 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 12 | 2018-05-03 |
| 20-F | Annual and transition report of foreign private issuers under sections 13 or 15(d) | 221 | 2018-04-06 |
| 6-K | Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act | 17 | 2018-03-23 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 3 | 1 | 1 | 1 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2020 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait